Xiaoqi Liu
Senior Director, Head of Business Development & Strategic Finance Degron Therapeutics
Seminars
Thursday 10th September 2026
Expansion Potential: Advancing Degradation into New Indications & Beyond “Classic” Degraders
8:45 am
- Highlighting innovations in non-E3 ligase mechanisms, and discussing which modality fits which disease class?
- Overcoming target identification bottlenecks for immunology and CNS targets. Should companies prioritize diseases with validated pathways but poor druggability, or tissues where degrader PK/ PD is already known?
- As pharma lean towards platforms with broad disease reach, what non-oncology data “moves the needle”?
